OUR TEAM

Board of Directors

Dr. Antonio Finelli, MD, MSc, FRCSC

Chair KCRNC

Dr. Antonio Finelli is a urologic oncologist and surgeon investigator at the University Health Network (UHN) in Toronto and a Full Professor at the University of Toronto. He is the Chief of Urology, GU Site Lead at the Princess Margaret Cancer Center, and the inaugural GU Oncology Lead for the province of Ontario (Cancer Care Ontario).

Dr. Finelli’s clinical practice focuses on the management of urologic malignancies with minimally invasive and robotic techniques. He has performed live surgery for instructional purposes in more than 10 countries. Dr. Finelli is recognized nationally and internationally for his contributions to minimally invasive urologic oncology.

Dr. Finelli conducts health services research in urologic oncology with an interest in identifying gaps in care and designing knowledge translation strategies to overcome them. He is also actively involved in clinical trials. He has published more than 100 peer-reviewed manuscripts and holds peer-reviewed funding for research in prostate and kidney cancer.

Simon Tanguay MD, FRCSC

Secretary KCRNC

Dr Tanguay is Professor and Chair of the Division of Urology at McGill University and holds the Mostafa Elhilali and David Azrieli Chair in urologic sciences.  He completed his residency training at McGill University and a fellowship in Urologic Oncology at the University of Texas M. D. Anderson Cancer Center.

Dr Tanguay served a member of the executive committee of the Genito-Urinary group of the National Cancer Institute of Canada, the Canadian Urological Association, the Quebec Urological Association and Société Internationale d’Urologie. He was the Chair of the Canadian Kidney Cancer information system from 2009 to 2016.  He is currently the Chair of the Medical Advisory board of Kidney Cancer Canada and member of the Board of Director of Kidney Cancer Canada.  His research interests are on genomic profiling and clinical outcomes of Renal Cell Carcinoma.  He was the General Secretary of the Société Internationale d’Urologie from 2011 to 2016 and served as President from 2018-2019.

Dr. Lori Anne Wood MD, MSc(Epi), FRCPC

KCRNC Treasurer

Dr. Wood is a Medical Oncologist at the Queen Elizabeth II Health Sciences Centre, Halifax, NS, as well as a Professor in the Department of Medicine at Dalhousie University with a cross-appointment in the Department of Urology. She completed her Medical Oncology training at the Cross Cancer Institute in Edmonton, Alberta, and a Master of Science in Epidemiology from the Harvard School of Public Health. She spent two years on faculty at the MD Anderson Cancer Centre, in Houston, Texas, in the Department of Genitourinary Oncology before moving to Halifax in 2000. Dr. Wood is an active member of the Nova Scotia Cancer Care Program Genitourinary Cancer Site Team. She is involved in all levels of undergraduate, postgraduate, and continuing medical education and serves as a mentor and supervisor for students and residents. Dr. Wood has a specific clinical and research interest in kidney cancer and is actively involved in phase II and III clinical trials as well as the Canadian Kidney Cancer Information System (CKCis) and the International Metastatic RCC Database (IMDC).

Dr. Aly-Khan A. Lalani, B.Sc (Hons), MD, FRCPC

KCRNC Board Director

Dr. Lalani is an Associate Professor at McMaster University and a Medical Oncologist at the Juravinski Cancer Centre (JCC). He is the Chair for the Genitourinary (GU) Cancers Disease Site Team at the JCC.

His academic interests include clinical trial design and translational work for GU malignancies. He is a Scientist with the Escarpment Cancer Research Institute, and an Associate Member of the Centre for Discovery in Cancer Research at McMaster University. He is also co-host of the podcast “The View on GU”.

Aly-Khan was awarded the Elizabeth Eisenhauer Early Drug Development Young Investigator Award from the Canadian Cancer Trials Group in 2022; and the Rising Star Award from the Canadian Association of Medical Oncologists in 2023. He has been appointed to Canada’s Drug Agency pan-Canadian Oncology Drug Review Expert Review Committee (pERC) since 2024.

Patrick Richard

KCRNC Board Director

Patrick Richard has obtained his MD from the Université de Sherbrooke and completed his urology residency at Sherbrooke and McGill University in 2013. He then completed a urologic oncology fellowship at the Princess Margaret Cancer Centre and a master in clinical epidemiology at the Institute of Health Policy, Management and Evaluation. He is an associate professor and research clinician at the Université de Sherbrooke since 2016. He was awarded the FRSQ Clinician Scientist Research Scholar- Junior 2 Award in 2022 and holds the CRMUS research chair in kidney cancer. He serves on the board of directors for the Kidney Cancer Research Network of Canada and on the guidelines steering committee for the Canadian Urological Association. He is also the author of several manuscripts, book chapters and guidelines. Dr. Richard research program aims at reducing overtreatment and burden of care in urological cancers, with a focus on kidney cancer.

Dr. Rodney Breau

CKCIS Chair

Dr. Breau is a surgical oncologist, scientist, and professor of urology at The University of Ottawa/Ottawa Hospital Research Institute. Dr. Breau serves or served on numerous American Urological Association and Cancer Care Ontario leadership committees and is currently the Chair of the CUA Guidelines Steering Committee. He is the primary investigator of several multicenter surgical trials in urologic oncology and is the co-lead of a national cohort study of patient with kidney cancer. Dr. Breau attended medical school at Dalhousie University and did his urology residency at the University of Ottawa. He completed his urologic oncology and robotic surgery fellowship at Mayo Clinic and received a Master of Science in clinical and translational research from Mayo School of Graduate Medical Education.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged.Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever

Dr. Naveen Basappa MD, FRCPC

CKCIS Co-chair

Dr. Naveen Basappa is a board-certified internist with a specialization in Medical Oncology. He graduated with a medical degree from the University of Alberta in 2003 and went on to earn dual fellowship certifications in Internal Medicine and Medical Oncology from the Royal College of Physicians of Canada. His comprehensive training and unwavering commitment to cancer care allow him to deliver thorough and empathetic treatment to patients dealing with complex cancer diagnoses.

Dr. Basappa’s expertise encompasses all aspects of oncology, including early diagnosis, personalized treatment planning, advanced therapies, and ongoing support. With a strong focus on patient-centered care, he customizes his approach to address the unique needs of each individual. Dr. Basappa integrates the latest scientific advancements with compassionate guidance, ensuring that patients and their families receive comprehensive support throughout their cancer journey.

In addition to his clinical work, Dr. Basappa serves as an Assistant Clinical Professor in the Department of Oncology at the University of Alberta.

Operation Staff

Contact

Address:

Princess Margaret Cancer Centre

610 University Ave. 3-130


Toronto ON M5G 2M9

Email:

info@kcrnc.ca

Chair

Project Manager

Dr. Antonio Finelli

Maria Komisarenko